The future of renal denervation to treat hypertension is in doubt after Medtronic PLC announced Jan. 9 that SYMPLICITY HTN-3
, the U.S. pivotal trial of the firm’s Symplicity system, missed its primary efficacy endpoint.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?